Virtual Library

Start Your Search

Y. Ogata



Author of

  • +

    P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Advanced Diseases - NSCLC
    • Presentations: 1
    • +

      P1.01-043 - Prognostic Factors in the First-Line Chemotherapy of Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with Performance Status 2 (ID 1428)

      09:30 - 17:00  |  Author(s): Y. Ogata

      • Abstract
      • Slides

      Background:
      To evaluate prognostic factors in the first-line chemotherapy of advanced non-squamous non-small cell lung cancer patients with Eastern Cooperative Oncology Group(ECOG) performance status(PS) 2.

      Methods:
      We retrospectively analyzed clinical and laboratory characteristics of patients with advanced non-squamous non-small cell lung cancer patients with ECOG PS 2 who received the first-line chemotherapy in our institute. We examined the various clinical values such as gender, age, clinical stage, histology, immunohistochemistry, chemotherapy regimen, underlying diseases, metastasis sites, data of blood test.

      Results:
      A total of 31 patients aged 45 to 80 years (median 65) were treated from August 2006 to February 2015(male/female;23/8, adenocarcinoma/non-small cell carcinoma;15/16). They were received single agent or combination chemotherapy(carboplatin and pemetrexed(CP);17, others;14). In univariate analysis, median survival times were 9.56 months in adenocarcinoma vs 3.26 months in non-small cell carcinoma(P=0.0011) , 16.77months in Thyroid Transcription Factor-1(TTF-1) expression positive(n=10) vs 4.96 months in TTF-1 expression negative(n=9)(P=0.0166), 2.59 months in 7.0ng/ml and over of CYFRA21-1 vs 9.56 months under 7.0ng/ml of CYFRA21-1(P=0.0236), 8.53 months in CP vs 2.20 months in others(P=0.0003). Objective response rates were 29.4% in CP and 0% in others.

      Conclusion:
      Our results show that patients who were diagnosed adenocarcinoma pathologically had significantly better prognosis than the others, and CP may attributes to good prognosis of the patients with advanced non-squamous non-small cell lung cancer patients with ECOG PS 2.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.06 - Poster Session/ Screening and Early Detection (ID 218)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Screening and Early Detection
    • Presentations: 1
    • +

      P1.06-025 - Statistical Analysis of 18F-FDG-PET/CT Findings of Ground Glass Nodule (GGN) (ID 1689)

      09:30 - 17:00  |  Author(s): Y. Ogata

      • Abstract
      • Slides

      Background:
      18F-FDG-PET/CT (PET/CT) is one of the most important image inspections for the diagnosis of lung cancer. However, there are often false negatives caused by small lesions such as Ground Glass Nodule (GGN). Whether PET/CT is useful for the diagnosis of GGN is unknown. Therefore, we analyzed the relationship of computed tomography (CT) findings (size, properties) and maximum standardized up-take values (SUV-max) of GGN.

      Methods:
      We had 69 patients with pathological-Stage IA-IB lung adenocarcinoma who underwent surgical resection and PET/CT from January 2010 to December 2014. We retrospectively examined their clinical characteristics, CT findings, and PET/CT findings.

      Results:
      Characteristics of 69 patients were as follows, 47 - 86 years old (median 70 years old), female/male: 39/30, pathological-Stage IA/IB: 59/10. GGN diameter: 1.1 - 41.13mm (median 19.43mm), Solid-part diameter: 0.0 - 23.23mm (median 4.55mm), Solid-part-ratio (solid-part diameter / GGN diameter): 0 - 77% (median 20%). SUV-max was insignificant to 6.8 (median 1.0). Correlation coefficient of each factor and SUV-max were as follows, GGN diameter: 0.49, Solid-part diameter: 0.54, Solid-part-ratio: 0.41 (Pearson’s product-moment correlation). All pure-GGN show no significant SUV-max (<2.5), even though there are some large GGN included (max 40.0mm). GGN diameter >20mm or solid-part diameter >5mm were significant factor of FDG-uptake (Fisher’s exact test). In this study, SUV-max was lower than significant level with solid-part diameter <4.55mm.

      Conclusion:
      There was no significant SUV-max with diagnostic value in pure-GGN. PET/CT is not useful for pure-GGN or small part-solid nodule (solid-part diameter <4.55mm). There is higher correlation in the solid-part diameter and SUV-max. We should keep in mind the limitation of PET/CT for GGN diagnosis.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.